Antibody therapies for melanoma: New and emerging, opportunities to activate immunity (Review)

Oncology Reports

Volumn 32, Issue 3, 2014, Pages 875-886

  Malas, Sadek ^a   Harrasser, Micaela ^a   Lacy, Katie E ^a   Karagiannis, Sophia N ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antibodies; Checkpoint blockade; Cytotoxicity; Effector cells; Host immunity; Immunosuppression; Immunotherapy; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; DACLIZUMAB; DENDRITIC CELL VACCINE; DNA VACCINE; GLYCOPROTEIN GP 100 VACCINE; IPILIMUMAB; MD 1379; NIVOLUMAB; PEGINTERFERON ALPHA2B; PEMBROLIZUMAB; PEPTIDE VACCINE; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELL INTERACTION; COLITIS; COMPLEMENT ACTIVATION; DERMATITIS; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EFFECTOR CELL; FATIGUE; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MELANOMA; METASTASIS INHIBITION; METASTATIC MELANOMA; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REGULATORY T LYMPHOCYTE; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL TIME; T CELL DEPLETION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; GENE; IMMUNOLOGY; IMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; GENES, CDC; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 84907651094     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3275     Document Type: Review

References (111)

1. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206, 2009.
2. Gerner RE, Moore GE and Dickey C: Combination chemotherapy in disseminated melanoma and other solid tumors in adults. Oncology 31: 22-30, 1975.
3. Atkins MB: Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12: 2353s-2358s, 2006.
4. Ballantyne AD and Garnock-Jones KP: Dabrafenib: first global approval. Drugs 73: 1367-1376, 2013.
5. Bollag G, Tsai J, Zhang J, et al: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11: 873-886, 2012.
6. Wright CJ and McCormack PL: Trametinib: first global approval. Drugs 73: 1245-1254, 2013.
7. Sznol M: Advances in the treatment of metastatic melanoma: new immunomodulatory agents. Semin Oncol 39: 192-203, 2012.
8. Oble DA, Loewe R, Yu P and Mihm MC Jr: Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9: 3, 2009.
9. Shimanovsky A, Jethava A and Dasanu CA: Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther 13: 1413-1427, 2013.
10. Cipponi A, Mercier M, Seremet T, et al: Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 72: 3997-4007, 2012.
11. Gilbert AE, Karagiannis P, Dodev T, et al: Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One 6: e19330, 2011.
12. Lacy KE, Karagiannis SN and Nestle FO: Advances in the treatment of melanoma. Clin Med 12: 168-171, 2012.
13. Fujimura T, Ring S, Umansky V, Mahnke K and Enk AH: Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol 132: 1239-1246, 2012.
14. Karagiannis P, Gilbert AE, Nestle FO and Karagiannis SN: IgG4 antibodies and cancer-associated inflammation: insights into a novel mechanism of immune escape. Oncoimmunology 2: e24889, 2013.
15. Karagiannis P, Gilbert AE, Josephs DH, et al: IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 123: 1457-1474, 2013.
16. Wang T, Ge Y, Xiao M, et al: Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res 25: 493-505, 2012.
17. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116, 1999. (Pubitemid 29318842)
18. Hauschild A: Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol 16: 3-6, 2009.
19. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K, et al: Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 33: 484-496, 2007. (Pubitemid 47333669)
20. Sasse AD, Sasse EC, Clark LG, Ulloa L and Clark OA: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev: CD005413, 2007.
21. Borden EC: Interferons: pleiotropic cellular modulators. Clin Immunol Immunopathol 62: S18-24, 1992.
22. Bart RS, Porzio NR, Kopf AW, Vilcek JT, Cheng EH and Farcet Y: Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Res 40: 614-619, 1980. (Pubitemid 10174878)
23. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC and Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7-17, 1996. (Pubitemid 26019991)
24. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A and Suciu S: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29: 241-252, 2003. (Pubitemid 37069655)
25. Hillner BE: Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma. Eur J Cancer 34: S18-S21, 1998.
26. Eggermont AM, Suciu S, Santinami M, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372: 117-126, 2008. (Pubitemid 351952257)
27. Cheever MA and Higano CS: PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17: 3520-3526, 2011.
28. Zikich D, Schachter J and Besser MJ: Immunotherapy for the management of advanced melanoma: the next steps. Am J Clin Dermatol 14: 261-272, 2013.
29. Dannull J, Haley NR, Archer G, et al: Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 123: 3135-3145, 2013.
30. Yuan J, Ku GY, Gallardo HF, et al: Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 9: 5, 2009.
31. Reichert JM and Dhimolea E: The future of antibodies as cancer drugs. Drug Discov Today 17: 954-963, 2012.
32. Azijli K, Stelloo E, Peters GJ and van den Eertwegh AJ: New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res 34: 1493-1505, 2014.
33. Price MA, Colvin Wanshura LE, Yang J, et al: CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res 24: 1148-1157, 2011.
34. Wang X, Osada T, Wang Y, et al: CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 102: 1496-1512, 2010.
35. Yang J, Price MA, Neudauer CL, et al: Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 165: 881-891, 2004. (Pubitemid 38821978)
36. Yang J, Price MA, Li GY, et al: Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to- mesenchymal transition. Cancer Res 69: 7538-7547, 2009.
37. Chekenya M, Krakstad C, Svendsen A, et al: The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene 27: 5182-5194, 2008.
38. Maciag PC, Seavey MM, Pan ZK, Ferrone S and Paterson Y: Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 68: 8066-8075, 2008.
39. Kusama M, Kageshita T, Chen ZJ and Ferrone S: Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol 143: 3844-3852, 1989. (Pubitemid 20007063)
40. Chen ZJ, Yang H, Kageshita T and Ferrone S: Human highmolecular- weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371. Cancer Res 51: 4790-4797, 1991.
41. Mittelman A, Chen ZJ, Yang H, Wong GY and Ferrone S: Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89: 466-470, 1992.
42. Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S and Ferrone S: Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1: 705-713, 1995.
43. Mittelman A, Wang X, Matsumoto K and Ferrone S: Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 14: 175-181, 1995.
44. Murray JL, Gillogly M, Kawano K, et al: Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 64: 5481-5488, 2004. (Pubitemid 39006572)
45. Torisu-Itakura H, Schoellhammer HF, Sim MS, et al: Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. J Immunother 34: 597-605, 2011.
46. Rybczynska AA, Dierckx RA, Ishiwata K, Elsinga PH and van Waarde A: Cytotoxicity of sigma-receptor ligands is associated with major changes of cellular metabolism and complete occupancy of the sigma-2 subpopulation. J Nucl Med 49: 2049-2056, 2008.
47. de Bruyn M, Rybczynska AA, Wei Y, et al: Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 9: 301, 2010.
48. Geldres C, Savoldo B, Hoyos V, et al: T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res 20: 962-971, 2014.
49. Mehnert JM, McCarthy MM, Jilaveanu L, et al: Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 41: 375-384, 2010.
50. Spinella F, Caprara V, Cianfrocca R, et al: The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis 35: 840-848, 2014.
51. Hsu JY and Wakelee HA: Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23: 289-304, 2009.
52. Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL and Slingluff CL Jr: Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 68: 4392-4397, 2008.
53. Del Vecchio M, Mortarini R, Canova S, et al: Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 16: 5862-5872, 2010.
54. Varker KA, Biber JE, Kefauver C, et al: A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14: 2367-2376, 2007. (Pubitemid 47174913)
55. Guenterberg KD, Grignol VP, Relekar KV, et al: A pilot study of bevacizumab and interferon-alpha2b in ocular melanoma. Am J Clin Oncol 34: 87-91, 2011.
56. Corrie PG, Marshall A, Dunn JA, et al: Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol 15: 620-630, 2014.
57. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP and Rosenberg SA: Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70: 6171-6180, 2010.
58. Perez DG, Suman VJ, Fitch TR, et al: Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 115: 119-127, 2009.
59. Perez EA, Hillman DW, Dentchev T, et al: North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol 21: 269-274, 2010.
60. Allison JP, Chambers C, Hurwitz A, et al: A role for CTLA-4 mediated inhibitory signals in peripheral T cell tolerance? Novartis Found Symp 215: 92-98, 1998.
61. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK and Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174: 561-569, 1991.
62. Simpson TR, Li F, Montalvo-Ortiz W, et al: Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210: 1695-1710, 2013.
63. Bulliard Y, Jolicoeur R, Windman M, et al: Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210: 1685-1693, 2013.
64. + regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 206: 421-434, 2009.
65. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377, 2003. (Pubitemid 36842552)
66. Weber JS, O'Day S, Urba W, et al: Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26: 5950-5956, 2008.
67. Ribas A, Camacho LH, Lopez-Berestein G, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23: 8968-8977, 2005. (Pubitemid 46217464)
68. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
69. Hersh EM, O'Day SJ, Powderly J, et al: A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy- naive patients with advanced melanoma. Invest New Drugs 29: 489-498, 2011.
70. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363: 711-723, 2010.
71. Callahan MK, Postow MA and Wolchok JD: Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 31: 191-199, 2013.
72. Postow MA, Callahan MK and Wolchok JD: The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? Clin Cancer Res 18: 1821-1823, 2012.
73. Della Vittoria Scarpati G, Fusciello C, Perri F, et al: Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 7: 203-209, 2014.
74. Ribas A, Kefford R, Marshall MA, et al: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31: 616-622, 2013.
75. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293-12297, 2002.
76. Hino R, Kabashima K, Kato Y, et al: Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116: 1757-1766, 2010.
77. Ahmadzadeh M, Johnson LA, Heemskerk B, et al: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544, 2009.
78. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175, 2010.
79. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030, 2014.
80. Lipson EJ, Sharfman WH, Drake CG, et al: Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19: 462-468, 2013.
81. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl J Med 369: 134-144, 2013.
82. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 366: 2455-2465, 2012.
83. Yao X, Ahmadzadeh M, Lu YC, et al: Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119: 5688-5696, 2012.
84. De Panfilis G, Campanini N, Santini M, et al: Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. J Invest Dermatol 128: 676-684, 2008. (Pubitemid 351252653)
85. + regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep 18: 1115-1122, 2007.
86. + T cells during aging. J Exp Med 206: 1929-1940, 2009.
87. Jacobs JF, Punt CJ, Lesterhuis WJ, et al: Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase III study in metastatic melanoma patients. Clin Cancer Res 16: 5067-5078, 2010.
88. Curran MA, Montalvo W, Yagita H and Allison JP: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107: 4275-4280, 2010.
89. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. New Engl J Med 369: 122-133, 2013.
90. Ly LV, Sluijter M, van der Burg SH, Jager MJ and van Hall T: Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. J Immunol 190: 489-496, 2013.
91. Alderson KL, Luangrath M, Elsenheimer MM, et al: Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG. Cancer Immunol Immunother 62: 665-675, 2013.
92. Flaherty KT: Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clin Exp Metastasis 29: 841-846, 2012.
93. Chapman PB, Hauschild A, Robert C, et al: Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol: 8502, 2012.
94. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365, 2012.
95. Knight DA, Ngiow SF, Li M, et al: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123: 1371-1381, 2013.
96. Ngiow SF, Knight DA, Ribas A, McArthur GA and Smyth MJ: BRAF-targeted therapy and immune responses to melanoma. Oncoimmunology 2: e24462, 2013.
97. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A and Mozzillo N: Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 10: 107, 2012.
98. Ribas A, Hodi FS, Callahan M, Konto C and Wolchok J: Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368: 1365-1366, 2013.
99. Culos KA and Cuellar S: Novel targets in the treatment of advanced melanoma: new first-line treatment options. Ann Pharmacother 47: 519-526, 2013.
100. Woof JM: Insights from Fc receptor biology: a route to improved antibody reagents. MAbs 4: 291-293, 2012.
101. Bossi G, Buisson S, Oates J, Jakobsen BK and Hassan NJ: ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother 63: 437-448, 2014.
102. McCormack E, Adams KJ, Hassan NJ, et al: Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother 62: 773-785, 2013.
103. Karagiannis SN, Josephs DH, Karagiannis P, et al: Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother 61: 1547-1564, 2012.
104. Josephs DH, Spicer JF, Karagiannis P, Gould HJ and Karagiannis SN: IgE immunotherapy: a novel concept with promise for the treatment of cancer. MAbs 6: 54-72, 2014.
105. Boross P, Lohse S, Nederend M, et al: IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 5: 1213-1226, 2013.
106. Lohse S, Brunke C, Derer S, et al: Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem 287: 25139-25150, 2012.
107. Lohse S, Derer S, Beyer T, et al: Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 186: 3770-3778, 2011.
108. Peggs KS, Quezada SA, Chambers CA, Korman AJ and Allison JP: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti- CTLA-4 antibodies. J Exp Med 206: 1717-1725, 2009.
109. Silina K, Rulle U, Kalnina Z and Line A: Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue? Cancer Immunol Immunother: Apr 3, 2014 (Epub ahead of print).
110. Cipponi A, Wieers G, van Baren N and Coulie PG: Tumorinfiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 60: 1153-1160, 2011.
111. Tsoka S, Ainali C, Karagiannis P, et al: Toward prediction of immune mechanisms and design of immunotherapies in melanoma. Crit Rev Biomed Eng 40: 279-294, 2012.